DIA 48th Annual Meeting
Click here to go to the previous page
Communicating Drug Safety Information Using Social Media: FDA and Industry Perspectives
Track
:
Track 06: Medical Writing and Medical Communications
Program Code:
158
Date:
Monday, June 25, 2012
Time:
3:30 PM to 5:00 PM
EST
CHAIR
:
Catherine Chew, FDA, United States
PRESENTER
(S):
Catherine Chew, FDA, United States Gregory Busse, FDA, United States
Sue James, GlaxoSmithKline, United States
Description
FDA relays the latest drug safety information through drug safety communications which are disseminated using social media tools. This session provides FDA and industry perspectives on the development, communication, dissemination, and impact of drug safety communications.
Learning Objectives:
Describe the development, dissemination, and impact of FDA Drug Safety Communications
Evaluate the reach and benefits of various social media tools
Differentiate between industry and FDA's reactions and efforts to communicate newly identified or potential drug risks to the public.
Learning Objectives:
Describe the development, dissemination, and impact of FDA Drug Safety Communications
Evaluate the reach and benefits of various social media tools
Differentiate between industry and FDA's reactions and efforts to communicate newly identified or potential drug risks to the public.
This session is a part of:
Handout Online
